• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BioHarvest Sciences to Host Third Quarter 2024 Earnings Call on November 25 at 4:30 P.M. Eastern Time

    11/18/24 8:30:00 AM ET
    $BHST
    Get the next $BHST alert in real time by email

    Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 18, 2024) - BioHarvest Sciences Inc. (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the third quarter ended September 30, 2024 after market close on Monday, November 25, 2024.

    Management will host an investor conference call at 4:30 p.m. Eastern time on Monday, November 25, 2024, to discuss BioHarvest's third quarter 2024 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:

    Third Quarter FY2024 Results Conference Call
    Date: Monday, November 25, 2024
    Time: 4:30 p.m. Eastern time
    U.S./Canada Dial-in: 1-844-825-9789
    International Dial-in: 1-412-317-5180
    Conference ID: 10194495
    Webcast: BHST Q3 FY2024 Earnings Conference Call

    Please dial in at least 10 minutes before the start of the call to ensure timely participation.

    A telephone playback of the call will be available through Monday, December 9, 2024. To listen, call 1-844-512-2921 within the United States and Canada or 1-412-317-6671 when calling internationally, using replay pin number 10194495. A webcast replay will also be available by clicking here: BHST Q3 FY2024 Earnings Conference Call.

    About BioHarvest Sciences Inc.

    BioHarvest Sciences Inc. (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

    Forward-Looking Statements

    Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

    Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

    This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.

    BioHarvest Corporate Contact:
    Dave Ryan, VP Investor Relations & Director
    +1 (604) 622-1186
    [email protected]

    Investor Relations Contact:
    Lucas A. Zimmerman
    Managing Director
    MZ Group - MZ North America
    +1 (949) 259-4987
    [email protected]

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/230394

    Get the next $BHST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHST

    DatePrice TargetRatingAnalyst
    5/5/2025$15.00Buy
    Craig Hallum
    12/18/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $BHST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and Additional $3.8 Million in Debt Reduction

    Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the Company's balance sheet with an additional $10.9 Million in gross proceeds and a concurrent $3.8 Million reduction in total debt.The following are the transactions which were executed subsequent to the Company's published Q2 2025 Financial Statements:Successfully raised $5.8 Million in incremental cash through the exercising of 898,277 w

    9/22/25 6:32:00 AM ET
    $BHST

    BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale

    Exosomes Produced in the Liquid Media of the BioHarvest Unique Large-Scale Bioreactors Add Potential New Revenue Stream from Products and CDMO OpportunitiesRehovot, Israel--(Newsfile Corp. - September 10, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and in its ability to generate new revenue streams.Exosomes are nano-sized extracellular vesicles naturally secreted by plant cel

    9/10/25 7:00:00 AM ET
    $BHST

    BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET

    Rehovot, Israel--(Newsfile Corp. - September 2, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will host a Virtual Investor Webinar on Wednesday, September 10, 2025 at 1:00 p.m. Eastern time.CEO Ilan Sobel will host the virtual investor webinar to provide a corporate update on new capability-building initiatives, the Company's 'Big Bets' for 2H 2025, and will conclude with a question-and-answer session from dial-in participants. To attend, please reference the access information below: Virtual Investor WebinarDate: Wednesday, September 10, 20

    9/2/25 8:30:00 AM ET
    $BHST

    $BHST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on BioHarvest Sciences with a new price target

    Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00

    5/5/25 8:30:45 AM ET
    $BHST

    Maxim Group initiated coverage on BioHarvest Sciences with a new price target

    Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00

    12/18/24 8:10:03 AM ET
    $BHST

    $BHST
    SEC Filings

    View All

    SEC Form 424B7 filed by BioHarvest Sciences Inc.

    424B7 - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    10/15/25 5:17:08 PM ET
    $BHST

    SEC Form 424B7 filed by BioHarvest Sciences Inc.

    424B7 - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    9/24/25 4:38:27 PM ET
    $BHST

    SEC Form 6-K filed by BioHarvest Sciences Inc.

    6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)

    9/23/25 3:41:41 PM ET
    $BHST

    $BHST
    Financials

    Live finance-specific insights

    View All

    BioHarvest Sciences Reports Second Quarter 2025 Financial Results

    Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product SalesRehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025.Second Quarter 2025 HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the second quarter of 2025 increased 41% year-over-year to $8.5 million, in line with management guidance, with gross margins of 60% expanding by 800 basis points y

    8/11/25 7:30:00 AM ET
    $BHST

    BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.m. Eastern Time

    Rehovot, Israel--(Newsfile Corp. - August 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the second quarter ended June 30, 2025 before market open on Monday, August 11, 2025.Management will host an investor conference call and webcast at 8:00 a.m. Eastern time on Monday, August 11, 2025 to discuss the Company's second quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:Second Q

    8/4/25 8:30:00 AM ET
    $BHST

    BioHarvest Sciences Reports First Quarter 2025 Financial Results

    First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.

    5/15/25 4:05:00 PM ET
    $BHST

    $BHST
    Leadership Updates

    Live Leadership Updates

    View All

    BioHarvest Announces Appointment of Sharon Malka to Board of Directors

    Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division

    1/22/25 8:30:00 AM ET
    $BHST